|
| LETTER TO EDITOR |
|
|
|
| Year : 2010 | Volume
: 42
| Issue : 3 | Page : 197-198 |
| |
Authors' reply
Richa Vaishya1, J Singh2, Harbans Lal1
1 Department of Biochemistry, Pt. BD Sharma Postgraduate Institute of Medical Science, Rohtak, Haryana, India
2 Department of Pharmacology, Pt. BD Sharma Postgraduate Institute of Medical Science, Rohtak, Haryana, India
| Date of Web Publication | 28-Jul-2010 |
Correspondence Address:
Richa Vaishya
Department of Biochemistry, Pt. BD Sharma Postgraduate Institute of Medical Science, Rohtak, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
PMID: 20871778 
How to cite this article:
Vaishya R, Singh J, Lal H. Authors' reply. Indian J Pharmacol 2010;42:197-8 |
Sir,
We thank Dr. Mahajan for his comments [1] on our paper. [2] Our reply to the queries are as follows:
- The study was planned to focus the beneficial effects of irbesartan in comparison to insulin and thus the relevance of the study remains clear.
- Suggestion at 2 is well-taken for future studies.
- We regret the typing error; please read group III for insulin and group IV for irbesartan.
- It is a printing error. The original [Table 1] and [Table
3] submitted to the journal office are reproduced here.
| » References | |  |
| 1. | Mahajan. Irbesartan in experimental diabetic nephropathy. Indian J Pharmacol 2010;42:197.   |
| 2. | Vaishya R, Singh J, Lal H. Biochemical effects of irbesartan in experimental diabetic nephropathy. Indian J Pharmacol 2009;41:252-4. [PUBMED] |
[Table 1], [Table
3]
|
